[Serum immunoglobulin concentrations in patients following bone marrow transplantation and preventive administration of high-dose nonspecific or normal-dose CMV-specific immunoglobulin].
Ten consecutive bone marrow transplant recipients were assigned alternatively to receive either a high dose polyspecific intravenous immunglobulin (HDIVIG) 0.5 g/kg weekly X 14, or a conventional dose of a CMV specific intravenous immunglobulin (CMVIG) 0.1 g/kg every three weeks. Before and after each application we determined the levels of total IgG, IgG subclasses, IgG 1, IgG 2, IgG 3, IgG 4, total IgA and IgM and of specific IgG and IgM antibody concentrations against endotoxin, lipid A, streptococcus A, hemophilus, EBV and CMV. In the HDIVIG, total IgG rose from 11 (median, range 2-11) g/l to 25 (22-32) g/l by day 89, in the CMVIG group, IgG dropped from 11 (10-15) g/l to 9 (6-12) g/l. In the same period the mean levels of IgG subclasses expressed as % of normal plasma pool increased in the HDIVIG group in all subclasses, not in the CMVIG group. The differences were significant, however, only for IgG 1 and IgG 2. IgG-antibodies against CMV, EBV, endotoxin, streptococcus and hemophilus did increase significantly in the HDIVIG group, but not in the CMVIG group. No increase was seen in both groups in lipid A antibodies and in specific IgM antibodies. Each application of CMVIG induced a transient increase of anti-CMV antibodies. We conclude that HDIVIG induces reproducibly an increase of specific and non-specific IgG antibodies. No attempt was made to assess clinical outcome. However, these results provide a rational basis for further therapeutic studies.
Berger
C
C
Abteilung für Hämatologie, Kantonsspital Basel.
Gratwohl
A
A
Doran
J E
JE
Scherz
R
R
Baumgartner
C
C
Morell
A
A
Bachmann
B
B
Spaeth
P J
PJ
Tichelli
A
A
Speck
B
B
D000328:Adult; D000918:Antibody Specificity / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007136:Immunoglobulins / Q000032:analysis*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D008297:Male; D009894:Opportunistic Infections / Q000276:immunology / Q000517:prevention & control*; D011446:Prospective Studies
D007074:Immunoglobulin G; D007136:Immunoglobulins
Serumimmunglobulinkonzentrationen in Patienten nach Knochenmarktransplantation und prophylaktischer Gabe von hoch-dosiert unspezifischem oder normal-dosiert CMV-spezifischem Immunglobulin.